Psoralen + ultraviolet A-treated psoriasis patients are at increased risk for squamous cell carcinomas and basal cell carcinomas; however, the incidence and risk factors associated with second squamous cell carcinomas and basal cell carcinomas in this population are not well quali®ed. Incidence and risk factors for second squamous cell carcinomas and basal cell carcinomas were studied in a cohort of 1380 psoralen + ultraviolet A-treated psoriasis patients prospectively followed for over 20 y; 264 had a squamous cell carcinoma and 258 a basal cell carcinoma after beginning psoralen + ultraviolet A therapy. After a ®rst squamous cell carcinoma, the risk of a second squamous cell carcinoma was 26% at 1 y, 62% at 5 y, and 75% at 10 y. Risk increased with high psoralen + ultraviolet A exposure prior to the ®rst squamous cell carcinoma (hazard ratio 3.32, 95% con®dence interval 1.53, 7.18). Higher rates of post®rst squamous cell carcinoma psoralen + ultraviolet A treatment also were associated with greater risk (hazard ratio 1.56 for every additional 10 treatments per year for patients with low pre-®rst squamous cell carcinoma psoralen + ultraviolet A exposure, 95% con®dence interval 1.35, 1.81). Patients exposed to high levels of tar and/or ultraviolet B before a ®rst squamous cell carcinoma were also at higher risk (hazard ratio 1.72, 95% con®dence interval 1.14± 2.60). Risk of a second basal cell carcinoma was 21% at 1 y, 49% at 5 y, and 61% at 10 y. There was some evidence that high exposure to psoralen + ultraviolet A before a ®rst basal cell carcinoma was associated with increased risk of second basal cell carcinoma (hazard ratio 1.45, 95% con®dence interval 0.97± 2.17). Higher post-®rst tumor psoralen + ultraviolet A treatment rates also increased risk (hazard ratio 1.24 for every additional 10 treatments per year, 95% con®dence interval 1.06±1.47). Psoralen + ultraviolet A-treated psoriasis patients appear to have a greatly increased incidence of second squamous cell carcinoma compared with the general population. Patients who develop a squamous cell carcinoma after starting psoralen + ultraviolet A therapy should be closely monitored for a subsequent squamous cell carcinoma.
Psoralen + ultraviolet A-treated psoriasis patients are at increased risk for squamous cell carcinomas and basal cell carcinomas; however, the incidence and risk factors associated with second squamous cell carcinomas and basal cell carcinomas in this population are not well quali®ed. Incidence and risk factors for second squamous cell carcinomas and basal cell carcinomas were studied in a cohort of 1380 psoralen + ultraviolet A-treated psoriasis patients prospectively followed for over 20 y; 264 had a squamous cell carcinoma and 258 a basal cell carcinoma after beginning psoralen + ultraviolet A therapy. After a ®rst squamous cell carcinoma, the risk of a second squamous cell carcinoma was 26% at 1 y, 62% at 5 y, and 75% at 10 y. Risk increased with high psoralen + ultraviolet A exposure prior to the ®rst squamous cell carcinoma (hazard ratio 3.32, 95% con®dence interval 1.53, 7.18). Higher rates of post®rst squamous cell carcinoma psoralen + ultraviolet A treatment also were associated with greater risk (hazard ratio 1.56 for every additional 10 treatments per year for patients with low pre-®rst squamous cell carcinoma psoralen + ultraviolet A exposure, 95% con®dence interval 1.35, 1.81). Patients exposed to high levels of tar and/or ultraviolet B before a ®rst squamous cell carcinoma were also at higher risk (hazard ratio 1.72, 95% con®dence interval 1.14± 2.60). Risk of a second basal cell carcinoma was 21% at 1 y, 49% at 5 y, and 61% at 10 y. There was some evidence that high exposure to psoralen + ultraviolet A before a ®rst basal cell carcinoma was associated with increased risk of second basal cell carcinoma (hazard ratio 1.45, 95% con®dence interval 0.97± 2.17). Higher post-®rst tumor psoralen + ultraviolet A treatment rates also increased risk (hazard ratio 1.24 for every additional 10 treatments per year, 95% con®dence interval 1.06±1.47). Psoralen + ultraviolet A-treated psoriasis patients appear to have a greatly increased incidence of second squamous cell carcinoma compared with the general population. Patients who develop a squamous cell carcinoma after starting psoralen + ultraviolet A therapy should be closely monitored for a subsequent squamous cell carcinoma. J Invest Dermatol 118: 1038±1043, 2002 S ince demonstrated in 1974 to be highly effective for psoriasis (Parrish et al, 1974) , orally administered psoralens and long-wave ultraviolet radiation (UVA) (PUVA) have been widely used to treat psoriasis.
Non-melanoma skin cancers (NMSC) increasingly account for morbidity and health-care costs as well as mortality (Preston and Stern, 1992 ). An estimated 1.3 million NMSC [approximately 20% squamous cell carcinomas (SCC) and 80% basal cell carcinomas (BCC)] will be diagnosed in the United States in 2001, making them the most common cancers in that country (Miller and Weinstock, 1994; Alam and Ratner, 2001 ).
Psoriasis patients not exposed to carcinogenic therapies do not appear to be at substantially increased risk for SCC or BCC compared with the general population (Stern et al, 1982a; Alderson and Clarke, 1983; Hogan et al, 1989; Lindelof et al, 1990) ; however, compared with the general population, PUVA-treated psoriasis patients have an increased risk of cutaneous cancers, including NMSC, particularly SCC and, to a lesser extent, BCC (Stern et al, 1979 (Stern et al, , 1984 Henseler et al, 1987; Stern and Lange, 1988; Forman et al, 1989; Bruynzeel et al, 1991; Lindelof et al, 1991; Chuang et al, 1992; Stern and Laird, 1994) .
In addition to PUVA, factors reported to increase risk of NMSC among PUVA-treated psoriasis patients include lighter skin type (Forman et al, 1989; Stern and Laird, 1994) , tar, and ultraviolet (UV) B treatments (Henseler et al, 1987; Maier et al, 1996) , X-ray therapy (Henseler et al, 1987) , and arsenic therapy (Honigsmann et al, 1980; Stern et al, 1984; Maier et al, 1996) . Methotrexate use was demonstrated to increase risk of NMSC in one report (Henseler et al, 1987) but not in an earlier study of the cohort analyzed in this paper (Stern et al, 1982b (Stern et al, , 1984 . Ionizing radiation therapy increased risk of NMSC in the cohort analyzed in this study in an early (Stern et al, 1979) but not a later analysis (Stern and Laird, 1994) . Finally, a recent report found cyclosporine use to be associated with an increased NMSC incidence in this cohort (Marcil and Stern, 2001 Incidence of second NMSC in the general population has been studied (Epstein, 1973; Bergstresser and Halprin, 1975; Robinson, 1987; Schreiber et al, 1990; Frankel et al, 1992; Marghoob et al, 1993) and recently reviewed and subject to a meta-analysis (Marcil and Stern, 2000) . Second NMSC among PUVA-treated psoriasis patients, however, have not been systematically assessed. Utilizing data from a cohort prospectively studied for more than two decades, this analysis quanti®es the incidence and risk factors of second SCC and BCC among PUVA-treated psoriasis patients.
MATERIALS AND METHODS
Study population and follow-up The PUVA Follow-up Study enrolled 1380 psoriasis patients at 16 centers in the United States in 1975 and 1976 . Data for this analysis were collected through July 1, 1999. During each of 18 follow-up cycles since enrollment, patients were telephoned and asked about number of PUVA treatments received as well as about health events, including skin cancer diagnoses. Dates, types, body locations, and numbers of reported skin tumors were con®rmed by pathology reports. Patients were asked about: (i) past X-ray and arsenic therapy at the time of enrollment; (ii) tar, UVB, and methotrexate therapy at entry and during each follow-up cycle; and (iii) cyclosporine use during each follow-up cycle. This analysis includes all patients who had at least 6 mo of follow-up after a ®rst postenrollment BCC or SCC.
De®nitions of variables and outcomes Separate analyses were done for SCC and BCC. Only prospectively ascertained SCC (not including SCC in situ or keratoacanthomas) or BCC occurring after ®rst treatment with PUVA were considered in the analysis. Tumors diagnosed during a 180 d``wash-out'' period after a ®rst tumor, including multiple tumors diagnosed on the same day as the index tumor, were not considered second tumors in this analysis. For incidence as well as hazard ratio calculations, time at risk was de®ned as beginning 6 mo after diagnosis of a ®rst SCC or BCC (i.e., after the``wash-out'' period) and ending with the diagnosis of a second SCC or BCC, respectively, or with loss to follow-up. Tumor dates and locations on the body were taken from pathology reports. Only tumors thought to be new primaries, rather than suspected recurrences, were counted as second tumors.
Age was the age at development of the ®rst tumor. Skin types were categorized in two groups, I±II or III±VI. Regions of the United States where patients initially received treatment were categorized as northern, middle, or southern, as in prior analyses (Stern et al, 1979) . Body locations of ®rst tumors were categorized as more (head or neck) or less (rest of body) sun exposed.
The number of PUVA treatments received through the interview cycle during which the ®rst tumor was diagnosed was categorized as low (0±159), medium (160±259), or high (260+). Exposure to X-ray therapy or arsenic therapy re¯ected patient self-reporting. Cyclosporine exposure was considered positive if a patient had used cyclosporine for at least three consecutive months. High tar and/or UVB exposure corresponded to 45 or more months of tar treatments and/or 300 or more UVB treatments by 1989, provided the ®rst SCC or BCC was diagnosed by 1989. Similarly, high methotrexate exposure re¯ected more than 3 y of therapy, again provided a ®rst SCC or BCC diagnosis by 1989.
Logistic regression models were initially ®tted using the raw number of post-®rst tumor PUVA treatments. Preliminary results that showed, counterintuitively, a protective effect of increasing PUVA treatments were hypothesized to re¯ect the fact that patients who did not develop second tumors had more time to receive more PUVA treatments. To correct for this, the number of post-®rst tumor PUVA treatments was divided by the number of years of follow-up, yielding a post-®rst tumor PUVA treatment rate that was used in all subsequent analyses. The rate was modeled using two variables, allowing simultaneous estimation of effects of a rate of zero, or an increasing rate of, PUVA treatments after the ®rst tumor. The reference group for this variable throughout the analyses is patients with a rate of nearly (but not) zero PUVA treatments per year.
Statistical analysis For univariate analyses, all variables were individually entered linearly into Cox proportional hazards models (Cox, 1972; Armitage and Berry, 1994; Collett, 1994) . In each analysis, only variables trending toward signi®cance in univariate analyses (p < 0.15) were entered into a multivariate model. Backward-stepwise procedures (Altman, 1991) were used to identify variables signi®cantly related to second tumor risk in multivariate analyses. Interactions between all variables in ®nal models were tested for signi®cance using likelihood ratio tests. Proportional hazards assumptions for each model were tested using score residuals (Collett, 1994; Stern Reference Manual, 1999) . Kaplan±Meier and predicted survival functions were generated using standard techniques. All statistical analyses were performed with Stata 6.0 (Stata, College Station, TX).
RESULTS
Baseline and follow-up characteristics Of 1380 PUVA Follow-up Study patients, 276 had a postenrollment SCC and 265 a postenrollment BCC before July 1, 1999. Of these, 264 with an SCC and 258 with a BCC had at least 6 mo of follow-up and were included in this analysis. Characteristics of these cohorts are shown in Table I . For the SCC cohort, median overall follow-up time was 2.5 y (minimum 0.5, maximum 22.5, 1080.2 total person-years of follow-up). For BCC, it was 3.3 y (minimum 0.5, maximum 21.5, 1326.6 total person-years of follow-up).
Based on Kaplan±Meier estimates (Fig 1) , the percentages with a second SCC at 1, 3, 5, 10, and 15 y were 26.2%, 49.7%, 62.1%, 75.1%, and 90.8%, respectively. For a second BCC the corresponding percentages were 21.1%, 40.8%, 49.2%, 61.4%, and 69.9%, respectively.
Univariate analyses of risk factors associated with second tumors In univariate analyses for both cohorts (Table II) , PUVA exposure prior to a ®rst tumor was signi®cantly related to risk of a second tumor of the same type. The rate of post-®rst tumor PUVA exposure was also associated with second tumor risk for both cohorts. Among patients who received a minimal (but nonzero) rate of post-®rst tumor PUVA treatments, risk of a second SCC or BCC increased linearly with the rate; however, for both tumor types, risk was, counterintuitively, higher among patients who received no post-®rst tumor PUVA treatments than those who received low rates. High tar and/or UVB exposure prior to the ®rst SCC was signi®cantly related to risk of developing a second SCC, and there was some evidence of a similar relationship for BCC. Treatment with methotrexate prior to developing a ®rst tumor was a signi®cant risk factor for a second SCC.
Multivariate analyses of risk factors associated with second tumors In multivariate analysis (Table III) , high pre-®rst tumor PUVA exposure remained a signi®cant risk factor in both cohorts. Patients with high pre-®rst SCC PUVA exposure had a hazard ratio of 3.32 (95% CI 1.53, 7.18) compared with those with low pre-®rst SCC PUVA exposure, assuming that both had very low (but nonzero) post-®rst SCC PUVA treatment rates.
For BCC (Table IV) , evidence for an association between pre®rst tumor PUVA exposure and risk of a second BCC was of borderline statistical signi®cance (p = 0.07). Nevertheless, because this ®nding was biologically plausible, it was kept in the multivariate model. For second BCC, patients with high pre-®rst SCC PUVA exposure had a hazard ratio of 1.45 (95% CI 0.97, 2.17) compared with patients with low pre-®rst BCC PUVA exposure, regardless of the post-®rst BCC PUVA treatment rate for either patient.
Higher rates of post-®rst tumor PUVA treatments were also signi®cant risk factors for both cohorts. For the SCC cohort only, risk associated with post-®rst tumor rates depended on pre-®rst tumor PUVA exposure (p < 0.01 for the interaction). The additional risk associated with every 10 treatment rate increase was highest among patients who had low pre-®rst tumor PUVA exposure (HR 1.56, 95% CI, 1.35, 1.81) and lowest among patients with high pre-®rst tumor PUVA exposure (HR 1.12, 95% CI 1.06, 1.18). As in univariate analyses, patients in either cohort who received no PUVA treatments after a ®rst tumor were at higher risk than those who received low rates of post-®rst tumor PUVA treatment. For second SCC, the magnitude of this risk also depended on the level of pre-®rst tumor PUVA exposure, with risks highest among patients with low exposure (HR 3.64, 95% CI 1.75, 7.56) and lowest among patients with medium exposure (HR 2.45, 95% CI 1.28, 4.69).
In the BCC cohort, risk associated with post-®rst tumor PUVA treatment rates was independent of pre-®rst tumor PUVA expos- VOL. 118, NO. 6 JUNE 2002 ure. The hazard ratio for every additional 10 treatments per year after a ®rst BCC was 1.24 (95% CI 1.06, 1.47). Patients with no post-®rst BCC PUVA treatments had a hazard ratio of 4.18 (95% CI, 2.54, 6.88) compared with patients with low (but nonzero) rates of treatment.
A high level of exposure to tar and/or UVB prior to a ®rst tumor was a risk factor only for second SCC and did not depend on pre®rst SCC PUVA exposure (HR 1.72, 95% CI 1.14, 2.60). Methotrexate was not a signi®cant risk factors for second SCC or BCC in the multivariate analyses.
Based on the multivariate models, predicted percentages of patients with various combinations of risk factors developing a second SCC or BCC over time are shown in Figs 2 and 3. Among patients with a ®rst SCC, 50% of highest-risk patients (group H in Fig 2) would be expected to have a second SCC in 0.9 y after thè`w ash-out'' period. By comparison, the model predicts that it would take 14.8 y after the``wash-out'' period for half of patients with the lowest-risk pro®le (group A in Fig 2) to have a second SCC. For patients with a ®rst BCC, the median predicted time to a second BCC is 2.8 y for highest-risk patients (group F in Fig 3) , whereas even after 20 y of follow-up less than half of the lowestrisk patients (group A in Fig 3) would be expected to have had a second BCC. DISCUSSION PUVA-treated psoriasis patients appear to have a higher incidence of second SCC than other populations studied. In this study's cohort, 26% had a second SCC in the ®rst year of follow-up after the 6 mo``wash-out'' period, compared with 9% of patients enrolled in a clinical trial of b-carotene to prevent skin cancer (Karagas et al, 1992) and 17% of patients living in south-east Arizona, a high-risk area (Schreiber et al, 1990) . Within 3 y, 47% of our cohort had had a second SCC, compared with an estimate of only 18% of patients in a meta-analysis (Marcil and Stern, 2000) . The 5 y incidence of a second SCC in our cohort (62%) was markedly higher than both the clinical trial (31%) (Karagas et al, 1992) and the Arizona study (» 20%) (Schreiber et al, 1990) . Owing to limited follow-up, no other study has reported a 10 y incidence of second SCC (75% in our cohort) or a 15 y incidence (91%). Additionally, as this analysis did not count as positive for second Figure 1 . Kaplan±Meier survival curves for PUVA-treated psoriasis patients in the PUVA Follow-up Study. The curves show the percentage of patients who developed either a second SCC after a ®rst postenrollment SCC or a second BCC after a ®rst postenrollment BCC. After a 6 mo``wash-out'' period, the 1 y, 3 y, 5 y, 10 y, and 15 y incidences of a second SCC were 26%, 50%, 62%, 75%, and 91%. Corresponding incidences for a second BCC were 21%, 41%, 49%, 61%, and 70%.
SCC 17 patients whose only subsequent SCC was during thè`w ash-out'' period, our estimates may be more conservative than those of other studies.
In contrast, second BCC incidence during the ®rst year of follow-up after the``wash-out'' period (21%) within the ranges of 1 y incidences reported in the clinical trial (17%) (Karagas et al, 1992) , the Arizona study (33%) (Schreiber et al, 1990) , and a report on a northern California cohort (20%) (Epstein, 1973) . The 3 y incidence (41%) was close to that reported in the meta-analysis (44%) (Marcil and Stern, 2000) . The 5 y incidence in this cohort (49%) was similar to the rate among patients in the clinical trial (41%) (Karagas et al, 1992) and the rate among the Arizona patients (» 50%) (Schreiber et al, 1990) . As for SCC, there are no studies that compare with the 10 and 15 y second BCC incidences in our cohortÐ64% and 70% in our cohort. As with the SCC cohort, conservative estimates of second BCC incidence may have resulted from the fact that 21 patients whose only subsequent BCC was diagnosed during the``wash-out'' period were not considered as positive for second BCC.
Greater exposure to PUVA before a ®rst tumor was signi®cantly and strongly related to risk of second SCC (p < 0.01) but only marginally associated with risk of a second BCC (p = 0.07). These VOL. 118, NO. 6 JUNE 2002 ®ndings accord with results from ®rst tumor studies in our cohort and other PUVA-treated psoriasis cohorts, which have found that PUVA increases SCC risk more than it does BCC risk (Stern and Lange, 1988; Forman et al, 1989; Bruynzeel et al, 1991; Chuang et al, 1992; Stern and Laird, 1994; Stern and Lunder, 1998) . For both types of tumors, risk of a second tumor increased with the yearly rate of post-®rst tumor PUVA treatments. The ®nding in the SCC cohort that this risk was inversely related to pre-®rst SCC PUVA exposure suggests that PUVA-associated SCC risk may begin to plateau once a certain level of total PUVA exposure has been achieved.
For both SCC and BCC, patients receiving no post-®rst tumor PUVA treatments at all had a higher risk of second tumors than those who received a low rate of post-tumor PUVA. This counterintuitive ®nding is most likely consistent with selection bias, which may have resulted if PUVA had been discontinued altogether at the time of the ®rst tumor for patients who were thought to be (and indeed were) at high risk for subsequent tumors, based on ®rst tumor size or appearance or the clinical appearance of the patient's skin. These same concerns about second tumor risk might also have led to more frequent clinical follow-up for these patients, increasing the chance of earlier detection (but not development) of second tumors compared with other patients.
The ®nding that high tar and/or UVB exposure before a ®rst SCC increased risk of a second SCC supports a prior observation of this association in ®rst NMSC's among PUVA-treated psoriasis patients (Henseler et al, 1987) . A similar effect was seen when cumulative high exposure to tar and/or UVB as of 1989 (regardless of date of ®rst tumor) was entered into logistic regression models. It is important to note that this analysis cannot distinguish the effects of topical tar, which is no longer widely used in treating psoriasis, from those of UVB, which is still widely used. Nevertheless, a history of extensive treatment with tar and/or UVB prior to a ®rst SCC should be considered in estimating the risk of further PUVA and/or UVB treatments. Lack of an association between cyclosporine and second tumors in multivariate analysis was somewhat surprising, given that cyclosporine has been shown to increase NMSC incidence in this cohort over the long term (Marcil and Stern, 2001 ) and in transplant recipients, particularly with regard to SCC (London et al, 1995) . The most likely explanation is a lack of power to detect an effect in this more focused analysis, limited to second tumors occurring at least 6 mo after a ®rst tumor rather than all tumors occurring during the entire follow-up experience of patients in the cohort.
After adjustment for other factors, no signi®cant effect of methotrexate was seen on risk of second tumors of either type, a ®nding consistent with prior investigations of this cohort (Stern et al, 1982b (Stern et al, , 1984 .
In contrast to some other studies of patients in the general population, our multivariate analyses found no association between risk of a second NMSC and age (Karagas et al, 1992) , male sex (Epstein, 1973; Karagas et al, 1992) , skin type (Robinson, 1987; Karagas et al, 1992) , region of the country where a participant received treatment (Karagas et al, 1992) , and the ®rst tumor's location on a sun-exposed area of the body (Frankel et al, 1992) . Differences in our ®ndings from those in general populations studied may re¯ect intrinsic biologic differences in NMSC related to PUVA and those with other etiologies. Alternatively, differences could be due to limited power in this study.
This study should allow both treating physicians and psoriasis patients exposed to various PUVA treatments to estimate better risks of developing a second tumor. Given the demonstrated high risk of developing second tumors, PUVA-treated psoriasis patients who have developed an NMSC would appear to merit at least a yearly examination for new NMSC. Patients at particularly highrisk might warrant more frequent examinations. Finally, as second tumor risk increases with an increasing rate of post-®rst tumor PUVA treatments, continuation of PUVA treatment after a ®rst NMSC among patients who have had only modest exposure to PUVA will require that physicians and patients balance risks of PUVA, including second tumors (and especially SCC), with the bene®ts it affords for the management of severe psoriasis.
